Evidence map›Paper›PMID 42340549›Full record

ArticleMolecular and cellular biochemistry2026

P2Y12-AMPKα2 signaling contributes to cardiomyocyte senescence in doxorubicin-induced heart failure.

Qianqian Niu, Huidan Wang, Mengyao Zhao, Hongdou Zhang, Rui Hao, Peiyao Liu, Lijuan Guo, Bulei Chen, Yuting Xi, Peng Li and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qianqian NiuSchool of Basic Medical Sciences, Henan Medical University, Xinxiang, 453003, China.
Huidan WangCollege of Pharmacy, Henan Medical University, Xinxiang, 453003, China.
Mengyao ZhaoSchool of Basic Medical Sciences, Henan Medical University, Xinxiang, 453003, China.
Hongdou ZhangCollege of Pharmacy, Henan Medical University, Xinxiang, 453003, China.
Rui HaoCollege of Pharmacy, Henan Medical University, Xinxiang, 453003, China.
Peiyao LiuSchool of Basic Medical Sciences, Henan Medical University, Xinxiang, 453003, China.
Lijuan GuoDepartment of Ultrasound, The First Affiliated Hospital of Henan Medical University, Weihui, 453100, China.
Bulei ChenCollege of Pharmacy, Henan Medical University, Xinxiang, 453003, China.
Yuting XiCollege of Pharmacy, Henan Medical University, Xinxiang, 453003, China.
Peng LiCollege of Pharmacy, Henan Medical University, Xinxiang, 453003, China.
Yaling YinSchool of Basic Medical Sciences, Henan Medical University, Xinxiang, 453003, China. yalingyin@xxmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX)-induced cardiotoxicity is closely associated with oxidative stress, DNA damage, and senescence-related cardiac injury. This study evaluated the protective effects of Floralozone against DOX-induced cardiac injury and explored the associated molecular changes. Floralozone alleviated DOX-induced cardiac dysfunction, myocardial structural damage, oxidative stress, DNA damage responses, and senescence-related changes in vivo and in vitro. These protective effects were accompanied by modulation of the P2Y12-AMPKα2-ASK1-MEK3-related stress signaling axis. These findings suggest that Floralozone may protect against DOX-induced cardiac injury by suppressing oxidative stress, attenuating DNA damage responses, and reducing senescence-related signaling.

Indexed as

AMP-Activated Protein KinasesCellular SenescenceDoxorubicinHeart FailureMyocytes, CardiacSignal TransductionAnimalsOxidative StressRatsAMP-Activated Protein KinasesDoxorubicinDoxorubicinFloralozoneHeart failureP2Y12Senescence

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.